Endo USA v. Gland Pharma: VASOSTRICT Vasopressin Patent Action Dismissed Without Prejudice
Endo USA asserted eight patents protecting its VASOSTRICT vasopressin injection product against generic challenger Gland Pharma in New Jersey federal court. The parties jointly stipulated to a dismissal without prejudice just 44 days after filing, leaving the door open for future proceedings.
Eight-Patent VASOSTRICT Dispute Ends Early via Bilateral Stipulation
On December 31, 2024, Endo USA, Inc. initiated a patent infringement action in the U.S. District Court for the District of New Jersey against Gland Pharma, Ltd., an Indian generic pharmaceutical manufacturer. The complaint asserted eight U.S. patents — all sharing application numbers in the US15/688xxx and US15/612xxx series — covering vasopressin injection formulations at 20 units/100ml and 40 units/100ml concentrations, the same strengths marketed by Endo under the VASOSTRICT brand.
The case closed on February 13, 2025, via a Stipulation and Order of Dismissal without prejudice — meaning both parties agreed to terminate the action and the court entered the order, but no adjudication on the merits occurred. A dismissal without prejudice expressly preserves the plaintiff’s right to refile the same claims, distinguishing it from a settlement-with-release or a dismissal with prejudice, which would bar future action on the same patents against the same party.
The 44-day duration is notably short even by pharmaceutical ANDA litigation standards and suggests the parties may have reached a private commercial arrangement — a licensing deal, agreed launch date, or consent agreement — without memorializing it in the public court record. The absence of any reported defendant counsel further suggests Gland Pharma may have engaged directly or resolved the matter before formally appearing. What drove the swift resolution, and whether any business terms underpin it, remains unknown from the public docket.
Filing to Dismissed without Prejudice in 44 days
44 days — resolved well before typical ANDA litigation, which often runs 2–3 years
Dismissed without prejudice: what this stipulated exit means for both parties
Stipulated dismissal without prejudice explained
A stipulation and order of dismissal without prejudice is a bilateral agreement by the parties to close a case, entered by the court as an order. Critically, ‘without prejudice’ means no claim has been adjudicated — Endo retains the full right to assert any or all eight patents against Gland Pharma again. No finding of infringement, invalidity, or non-infringement was made.
No merits rulingEndo keeps all litigation options intact
Because the dismissal is without prejudice, Endo’s eight vasopressin patents remain enforceable and unchallenged on the merits. Endo can refile in New Jersey or another jurisdiction if Gland Pharma’s generic product enters the market on terms Endo finds unacceptable. The public record does not confirm whether a license or consent agreement was reached.
Patents survive intactGland Pharma faces no injunction — but no clearance either
The dismissal without prejudice gives Gland Pharma no declaratory judgment of non-infringement or invalidity. The generic maker has not secured freedom to operate through this litigation exit. If Gland Pharma launches its vasopressin product, it does so at risk of a renewed infringement action by Endo on any or all eight asserted patents.
No FTO establishedPrivate deal likely; generic market entry timeline uncertain
The 44-day resolution and joint stipulation are consistent with a confidential commercial arrangement — such as an authorized generic agreement, a delayed-entry license, or a negotiated launch date. Such arrangements are common in pharmaceutical patent settlements. However, none of these terms are confirmed in the public record. Market participants watching the vasopressin injection space should monitor Gland Pharma’s ANDA status for any approved launch date.
Watch generic launch timingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ENDO USA, INC. | Company | Pharmaceutical company — holder of US9925234B2 and 7 vasopressin formulation patentsSearch in Eureka ↗ |
| Defendant | Gland Pharma, Ltd. | Company | India-based generic pharmaceutical manufacturer seeking U.S. market entry for vasopressin injectionSearch in Eureka ↗ |
| Plaintiff counsel | Kaan Ekiner | Attorney | Counsel for ENDO USA, INC.Search in Eureka ↗ |
| Plaintiff law firm | Cozen O’connor PC | Law Firm | Representing ENDO USA, INC.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text — ‘Stipulation and Order of Dismissal without prejudice’ — reflects a consensual procedural exit rather than any judicial determination on the merits. Both parties agreed to close the case, and the court entered the order without ruling on infringement or validity. The ‘without prejudice’ designation is the operative phrase: it expressly preserves Endo’s right to refile the same claims against Gland Pharma in future proceedings, which distinguishes this outcome from a settlement with a mutual release or a judgment of non-infringement.
US9925234B2 and 7 co-filed vasopressin formulation patents — VASOSTRICT portfolio
The eight asserted patents — US9925234B2, US9925233B2, US9974827B2, US9962422B2, US9968649B2, US10010575B2, US9919026B2, and US9981006B2 — form a tightly clustered portfolio, with application numbers concentrated in the US15/688xxx series, suggesting they were filed as a coordinated family around the same period. They cover vasopressin injection formulations sold commercially as VASOSTRICT, a critical-care vasopressor used in the treatment of vasodilatory shock. The patents span formulation, concentration, and potentially method-of-use claims, creating overlapping layers of protection.
VASOSTRICT has faced sustained generic competition pressure, and Endo’s strategy of asserting eight patents simultaneously reflects pharmaceutical lifecycle management at scale. For competitors or generic manufacturers, clearing even a subset of these patents through IPR or litigation carries significant cost. The clustering of application numbers suggests the patents share common priority and may be subject to obviousness-type double patenting challenges — a vulnerability IP teams at potential challengers should assess carefully.
Should you run an FTO against Endo’s VASOSTRICT vasopressin patent portfolio?
Any company developing, manufacturing, or seeking FDA approval for a generic vasopressin injection product — whether at 20 units/100ml, 40 units/100ml, or related concentrations — should conduct a freedom-to-operate analysis against all eight asserted patents before committing to commercialisation. The dismissal without prejudice in this case provides no legal clearance whatsoever. Endo retains full enforcement rights across the entire portfolio.
PatSnap Eureka’s FTO Search Agent allows pharmaceutical R&D and regulatory teams to map claim scope across all eight patents, identify design-around opportunities, and flag potential invalidity arguments based on prior art. Given the clustered priority dates and shared application number series, a coordinated FTO across the full family — rather than patent-by-patent analysis — will surface the most actionable insights for generic development strategy.
Run a freedom-to-operate analysis on US9925234B2 to assess your product’s exposure
Run FTO in Eureka →Similar vasopressin and pharmaceutical ANDA patent cases in New Jersey federal court
Explore related ANDA infringement actions involving vasopressin or branded injectable pharmaceuticals litigated in the District of New Jersey.
What this case signals for the vasopressin and branded pharmaceutical IP landscape
A swift, stipulated exit on eight patents rarely happens without commercial context. Here is what IP professionals should take away.
Without-prejudice exits preserve enforcement leverage — use them strategically
Patent holders facing generic ANDA challengers can use a dismissal without prejudice as a negotiating tool — closing a case quickly while retaining the right to refile if a private deal later breaks down. Endo’s approach here is consistent with that playbook and avoids costly litigation on eight patents simultaneously.
Eight co-pending patents on one product signals a layered IP fortress strategy
Filing eight patents across related application numbers on a single product — VASOSTRICT — is a classic pharmaceutical lifecycle management strategy. Each patent may cover a different formulation variable, concentration, or method of use, increasing the cost and complexity for any generic challenger seeking to design around or invalidate the portfolio.
ENDO v Gland — key questions answered
The dismissal without prejudice means the court closed the case on the parties’ joint request without ruling on the merits. Endo USA retains the right to refile its infringement claims based on any or all eight vasopressin patents against Gland Pharma. No finding of infringement, validity, or non-infringement was made.
Endo asserted eight patents: US9925234B2, US9925233B2, US9974827B2, US9962422B2, US9968649B2, US10010575B2, US9919026B2, and US9981006B2. All relate to vasopressin injection formulations corresponding to the VASOSTRICT 20 units/100ml and 40 units/100ml products.
The 44-day resolution is unusually swift for ANDA pharmaceutical patent litigation. The joint stipulation and absence of any defendant counsel on the docket suggest the parties may have reached a private commercial arrangement — such as a licensing deal or authorized generic agreement — before the litigation formally progressed. No public terms have been disclosed.
No. The dismissal without prejudice establishes no legal clearance for Gland Pharma. The eight Endo vasopressin patents remain in force and unchallenged on the merits. Any commercial launch of a generic vasopressin injection product by Gland Pharma would still carry infringement risk under the asserted portfolio.
VASOSTRICT (vasopressin injection) is a critical-care vasopressor used to raise blood pressure in patients with vasodilatory shock. As a branded pharmaceutical product with FDA approval, it is protected by patents listed in the Orange Book. Generic manufacturers seeking approval via ANDA must certify they do not infringe — or challenge — those listed patents, which triggers potential litigation under the Hatch-Waxman Act framework.
PatSnap Eureka searches patents and litigation data to answer instantly.